Table 3.

Univariate log-rank analysis for important clinicopathological variables and SERPINB5 expression

Parameter		No. of case (%)	Disease-specific survival		Local recurrence-free survival		Metastasis-free survival
			No. of event	P	No. of event	P	No. of event	P
Gender	Male	108 (62.8)	20	0.9026	7	0.2250	17	0.3520
	Female	64 (37.2)	11		20		14
Age	<70	106 (61.6)	19	0.8540	18	0.6615	20	0.7427
	≥70	66 (38.4)	12		9		11
Pre-CCRT T stage	T1-T2	81 (47.1)	10	0.0776	10	0.2261	11	0.1745
	T3-T4	91 (52.9)	21		17		20
Pre-CCRT N stage	N0	125 (72.7)	19	0.0711	15	0.0070*	19	0.0973
	N1-N2	47 (27.3)	21		12		12
Pre-CCRT CEA	≤5 ng/ml	114 (66.3)	15	0.0216*	13	0.0179*	17	0.1460
	>5 ng/ml	58 (33.7)	16		14		14
Post-CCRT T stage	yT0-yT2	86 (50.0)	7	0.0006*	7	0.0040*	8	0.0033*
	yT3-yT4	86 (50.0)	24		20		23
Post-CCRT N stage	yN0	123 (71.5)	21	0.5998	16	0.1320	20	0.4634
	yN1-yN2	49 (28.5)	10		11		11
Lymphovascular invasion	Absent	157 (91.3)	25	0.0184*	21	0.0028*	27	0.4470
	Present	15 (8.7)	6		6		4
Perineural invasion	Absent	167 (97.1)	29	0.2559	25	0.0940	30	0.9083
	Present	5 (2.9)	2		2		1
Tumor regression grade	Grade 0-1	37 (21.5)	13	0.0038*	10	0.0090*	14	0.0006*
	Grade 2-3	118 (68.6)	17		17		16
	Grade 4	17 (9.9)	1		0		1
SERPINB5 expression	Low Exp.	86 (50.0)	6	0.0001*	9	0.0248*	4	<0.0001*
	High Exp.	86 (50.0)	25		18		27

*, statistically significant